Navigation Links
Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace
Date:3/18/2009

Establishing Wholly-owned Subsidiary to Enable BBK Worldwide to Better Serve Asia-Pacific Clinical Trial Enrollment Concerns

NEWTON, Mass., March 18 /PRNewswire/ -- BBK Worldwide, a global leader in patient recruitment for clinical trials, has announced the opening of BBK Worldwide -- Osaka, G.K., in Osaka, Japan. The company will be committed to supporting Japanese pharmaceutical, biotechnology, and medical device companies, as well as CROs and SMOs, to help these groups more rapidly and effectively enroll and retain patients as participants in clinical research studies.

Throughout the world, the single most costly delay in bringing new treatments to market is the slow enrollment of clinical trials, with each day a trial doesn't enroll potentially equivalent to millions of dollars in lost revenue due to treatment patent limitations. Moreover, it takes an average of 2.5 years longer for a drug to become available in Japan than in the U.S. or Europe, according to Japan's Pharmaceuticals and Medical Devices Agency (PMDA).

Understanding the primary causes for this specific delay was the first step for BBK in exploring the Japanese marketplace, according to company co-founder and president Bonnie Brescia. "We conducted in-depth interviews with medical directors and leaders of clinical trial teams at many of the major Japanese pharmaceutical companies," said Brescia, "And we found that four of the five top reasons for delay were issues that we have solved for our clients' studies in more than 30 countries throughout the world. Inefficient patient accrual, contracting with sites, attitudes of patients or referring physicians, and insufficient or inaccurate enrollment feasibility planning -- when we heard these concerns, we knew that we could offer real value to the Japanese marketplace."

"While we believe we can offer expert consultation and services immediately for study sponsors with recruitmen
'/>"/>

SOURCE BBK Worldwide
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
2. Pathway for Biosimilars Act Protects Patients, Promotes Competition, Preserves Innovation and Creates Quality Jobs, Lilly Says
3. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
4. Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions
5. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
6. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
7. Oregon Health & Science University Knight Cancer Institute Enhances Patient Care With Monaco(R) Radiation Treatment Planning System
8. Mayo Clinic CEO Offers New Vision for Personalized Patient Care
9. Photos: Project Runways Tim Gunn Launches Addressing Psoriasis(TM) Campaign to Advocate That Patients Shouldnt Let Psoriasis Impact Personal Style
10. NPSF Issues New Universal Patient Compact During Patient Safety Awareness Week
11. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DALLAS and NEW YORK ... (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing patient care ... public offering of 3,500,000 shares of common stock, and ... of common stock, at an offering price of $4.00 ... a per share exercise price of $5.00, are exercisable ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... will hold its 2015 Annual Meeting of Stockholders on ... the expected date for the Annual Meeting represents a ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn ... biotechnology company, Syngenta, are in the process of being ... The consolidated case is In Re: Syngenta AG MIR ... District Court for the District of Kansas. , Management ... been handed over to U.S. District Judge John W. ...
(Date:12/24/2014)... 23, 2014 SoundConnect’s ... designed to introduce cutting edge communication technology, ... partners of platform upgrades. This webinar series ... users in their quest to leverage web ... According to SoundConnect’s Marketing Manager, Seanna Baumgartner, ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... , , , , , , ... Synthesis with the new Transcriptor Reverse, Transcriptase , ... With the new recombinant ,Transcriptor Reverse Transcriptase, you will , , , ... cDNA transcripts , Reverse transcribe difficult templates with high secondary structure , ...
... , , , , , ... , , Co-transfections , ... DNA constructs work in your cell line. Also, determine the ratio of DNA ,to FuGENE ... ,provides good expression levels. Then, perform the transfection, ensuring the ,DNA / FuGENE 6 Reagent ...
... , , , , ... FuGENE 6 Transfection Reagent in Vector-based shRNA Experiments , ... RNA interference induced by siRNAs or shRNAs allows reliable down-regulation of ... into cells are used directly for transient gene silencing, ,vectors that encode for the ...
Cached Biology Technology:Transcriptor Reverse Transcriptase 2Transcriptor Reverse Transcriptase 3Transcriptor Reverse Transcriptase 4Transcriptor Reverse Transcriptase 5Uses and Applications of FuGENE 6 Transfection Reagent 2
(Date:12/17/2014)... 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... technology than the iPhone 5S, Samsung introduces for ... product. The Galaxy S5 home button ...
(Date:12/17/2014)... 2014  HITLAB SM announced today its ... to confirm its adherence to current U.S. Food ... HITLAB to conduct regulated smart device and smart ... patient safety and research quality. "HITLAB ... and delivery with innovative technology," said Laura ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... drugs currently studied in clinical trials appears to reduce ... at Georgetown University Medical Center report in an upcoming ... They say the results suggest that this class of ... been able to do-- prevent the long-term and continuing ...
... the specific biological mechanisms believed to lead to ... Diamond Blackfan anemia (DBA). Scientists say with further ... to current thinking about treatment for this disease ... George Thomas, PhD, Stefano Fumagalli, PhD, ...
... or ,gloopiness, of different parts of cancer cells increases ... according to new images that provide fundamental insights into ... today (15 March). The ... cells whilst they are dying as a result of ...
Cached Biology News:Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 2Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 3Cellular discovery may lead to targeted treatment for rare form of anemia 2Cellular discovery may lead to targeted treatment for rare form of anemia 3A sticky business -- how cancer cells become more 'gloopy' as they die 2
Rad 51C Immunogen: His-tagged human Rad 51C, over-expressed in E. coli Storage: 4 C...
...
...
... recognizes 30% of IgM-rheumatoid factor ... does not cross-react with IgM, IgA, ... nor with pooled F(Ab)2 fragments. This ... to detect rheumatoid factor. Product Category: ...
Biology Products: